OncoPharm

AMPLIFY Feb 20, 2025

We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL. Link: DOI: 10.1056/NEJMoa2409804

OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T Feb 13, 2025

Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports. 1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2. CD4+ T-cell lymphoma harboring a CAR integration into TP53: https://www.nejm.org/doi/full/10.1056/NEJMoa2411507

[Re-release] Rituximab Feb 06, 2025

Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?

Acalabrutinb + BR and sotorasib + panitumumab Jan 30, 2025

FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

Datoptamab deruxtecan Jan 22, 2025

Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

Dex Dosing in MM, Tec-Tal, & postMONARCH Jan 16, 2025

HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBR Dexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

Breakwater, Ensartinib, & SC Nivo Jan 09, 2025

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

The Accelerated Approval Pathway Jan 02, 2025

Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer. Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

2024 New Drug Review Dec 19, 2024

Looking back at new approvals from 2024 - what to keep, re-gift, or return? And yes, as soon as this was recorded 2 new drugs were approved.

A Feast Of Updates Dec 12, 2024

Lots of recent clinical trial updates to discuss: AQUILA: Daratumumab for high-risk smoldering multiple myeloma Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer SONIA: finally published!

Zenocutuzumab Dec 05, 2024

A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

Revumenib Nov 21, 2024

The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias. Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

Anthracycline Use In Breast Cancer Nov 14, 2024

A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191

SWISH Nov 07, 2024

Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib. SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2 Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001

Zolbetuximab Oct 31, 2024

The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!

S1826 & INTERLACE Oct 24, 2024

Discussing two excellent articles from earlier this month. S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888) & INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)

Inavolisib Oct 17, 2024

A new PIK3Ca inhibitor is approved for breast cancer.

Autumnal (2024) AML Updates Oct 10, 2024

Reviewing 3 recent AML publications Double-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235 AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631 Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2

MSI-High Rectal Cancer Treatment Oct 03, 2024

MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space. Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2

NATALEE + a slew of FDA updates Sep 26, 2024

FDA has been busy the last week approving: -ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma

ESMO 2024 Sep 19, 2024

Recapping just some of the notable data coming out of ESMO 2024: -Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC) -AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer) -ADRIATIC (discussed on ASCO recap Pod, but publication now available) -LEANOX (impact of lean body mass adjustment on oxaliplatin dose)

Doxorubicin + Trabectedin Sep 05, 2024

LMS04 final OS results are published for doxorubicin + trabectedin in Leiomyosarcoma. Plus, a natural experiment of what happens in small cell lung cancer during an IV etoposide shortage. Finally, a nice paper provides some examples of how oncology pharmacists can bridge the care gap between oncology and primary care. LMS04: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2403394 IV etoposide shortage: https://doi.org/10.1200/OP.24.00394 Primary care - oncology pharmacy collaboration: https://doi.org/10.1177/10781552241279303

Chapter 1. Doses Matter Aug 29, 2024

This is chapter 1 of a keynote address from summer 2024 on putting together the pieces of oncology pharmacy - with an emphasis on how our knowledge of drug dosing changes with time. Video/slides available at YouTube: https://youtu.be/1Oae8AV5Af4

Cross-Trial Comparison Don'ts Aug 22, 2024

We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.

Olanzapine For MEC Aug 15, 2024

A mixed bag of Phase III results for using olanzapine with moderately emegotenic chemotherapy (MEC). Inui, et al: https://doi.org/10.1200/JCO.24.00278 Ostwal, et al: doi:10.1001/jamanetworkopen.2024.26076

Afamitresgene Autoleucel & Vorasidenib Aug 08, 2024

A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.

Perioperative ICI Trial Design & Blood Test Screening For Colorectal Cancer Jul 31, 2024

FDA appears to change its stance on evaluating perioperative (adjuvant followed by neoadjuvant) ICI study designs in NSCLC. Also, a simple blood test is approved to detect colorectal cancer, but there are several limitations compared to colonoscopy.

The Auto Transplant Breast Cancer Scandal Jul 25, 2024

Did you know high-dose chemotherapy with autologous stem cel rescue was a "standard" breast cancer treatment ~30 years ago? This story involves changing practices based on Phase II data and outright clinical trial fraud, and retractions of publications. On-site review of Bezwoda study: https://doi.org/10.1016/S0140-6736(00)90024-2 Oral History: https://cancerhistoryproject.com/institutions/nccns-bob-carlson-talks-about-the-day-he-stormed-out-of-a-meeting-with-transplanters/

Vacation Reflections Jul 18, 2024

Reflections from vacation on 1) How similar the chef training experience on The Bear mirrors some pharmacy residency training and 2) being a resource to family/friends with oncology questions.

June '24 Updates & ATOPP Travelogue Jul 03, 2024

Running through recent updates on epcoritamab, adagrasib + cetuximab for colorectal cancer, endometrial cancer, adjuvant dabrafenib/trametinib melanoma follow-up data, and topical capsaicin for delayed CINV. Also, a brief travelogue on my inaugural trip to ATOPP (advanced topics for oncology pharmacy professionals) Summit.

MARIPOSA Jun 27, 2024

The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.

ViPOR Jun 21, 2024

An experimental regimen for DLBCL piques my interest. Venetoclax ibrutinib Prednisone Obinutuzumab Revlimid (lenalidomide) Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532

Imetelstat, Targeting Telomerase Jun 13, 2024

A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.

ASCO 2024 Jun 06, 2024

Lots and lots of updates from the past weekend's ASCO annual meeting. 1. ADRIATIC (consolidation durvalumab in limited stage SCLC) 2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma) 3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer) 4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer) 5. TRANSMET (liver transplantation in colon cancer with liver mets) 6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus) 7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT) 8. CROWN (5 year update of lorlatinib in ALK+ NSCLC) 9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting) 10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)

Updated ASCO-ONS Antineoplastic Safety Standards May 30, 2024

ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon. Link: https://doi.org/10.1200/OP.24.00216

Tarlatamab May 23, 2024

A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.

QT Prolongation In Oncology May 16, 2024

QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.

Pro-MACE-CytaBOM May 09, 2024

The non-Award Winning series of Landmarks in OncoPharm returns to discuss a Next Big Thing in NHL that wasn't any better than plain old CHOP. From April 1993, it's Pro-MACE-CytaBOM Link: https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations May 02, 2024

Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data. A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754 What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160

Late April Updates Apr 25, 2024

Lots of recent updates to cover this week... 1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695) 2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358) 3. A cytokine-fusion protein, nogapendekin alfa inbakicept, is approved for intravesicular use in BCG-unresponsive bladder cancer. This agent appears to activity in NSCLC too... 4. The Phase II APPLE trial provides some evidence than deferring osimertinib to the second-line setting in metastatic EGFR-mutated NSCLC may yield similar OS to first-line use of osimertinib. (https://doi.org/10.1200/JCO.23.01521) 5.The METALLICA study provides a nice roadmap for empiric metformin use when starting alpelisib (https://doi.org/10.1016/j.eclinm.2024.102520) 6. Does CPX-351 cause less intestinal damage than 7 + 3? And could that explain the discordance between time of neutropenia and infection rates? A mouse model suggests yes. (https://doi.org/10.1200/jco.2017.77.6112)

NSCLC In A Nutshell Apr 19, 2024

Arguably, the most anticipated release of 4/19/24

HOPA '24, Site Agnositc T-DXd, & ALINA Apr 11, 2024

What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.

Tumor Lysis Syndrome Apr 04, 2024

Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.

Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT Mar 28, 2024

Discussing four papers that caught our eyes from the last few weeks: Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage. ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544 Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795 An RNA assay to predict gemcitabine sensitivity: https://doi.org/10.1200/JCO.22.02668 Management of skin cancers with ICIs in kidney transplant patients: https://doi.org/10.1200/JCO.23.02570

Colon Cancer Screening Wars Mar 14, 2024

Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test. How do they compare to the gold standard of colonoscopy? Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714 Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336

Bladder Cancer Updates Mar 07, 2024

EV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer. Also, nivolumab gets a 1st-line FDA approval for urothelial carcinoma in conjunction with cisplatin + gemcitabine based on CHECKMATE-901.

SPARED & D-TORCH Feb 29, 2024

Two nice studies have been recently published in the supportive care realm. SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy. D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome. SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730

Lifileucel & FLAURA2 Updates Feb 22, 2024

An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.

NAPOLI 3, POUT, & Ivosidenib - Azole DDIs Feb 15, 2024

New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals. NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1 POUT (final OS): https://doi.org/10.1200/JCO.23.01659 Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251

Small Cell Carcinoma, Prostate Edition Feb 08, 2024

You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.

Rethinking Some Fundamental Considerations Feb 01, 2024

In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask: Do we need a Port or PICC for every testicular cancer patient? Study: https://doi.org/10.1200/OP.23.00580 Editorial: https://doi.org/10.1200/OP.23.00730 Is vaginal estrogen safe if breast cancer patients? Study: https://jamanetwork.com/journals/jamaoncology/article-abstract/2811413 Does paclitaxel work differently than we always thought? Study: https://doi.org/10.1371/journal.pbio.3002339

Jan 2024 Updates... Jan 25, 2024

...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer. Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571) & FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)

Development Of Generic Lenalidomide with Dr. Ryan Beechinor Jan 10, 2024

Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen! Link: https://doi.org/10.1016/j.jcpo.2023.100446

Lenalidomide Jan 04, 2024

Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.

2023 New Drug Review Dec 21, 2023

A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.

ASH23 Appetizers Dec 14, 2023

Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.

VISTA Dec 07, 2023

Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone. VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479

Gamma Secretase Inhibition et al Nov 30, 2023

The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling. Review article: https://doi.org/10.1002/onco.13627 Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?

Repotrectinib & Capivasertib Nov 23, 2023

FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.

Fruquintinib And Osimertinib-Chemo in Combo? Nov 16, 2023

This week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.

Elderly AML & Burkitt Lymphoma Updates Nov 09, 2023

Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice. We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9) Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)

Landmarks Of Stage III NSCLC Nov 02, 2023

Out Landmarks of OncoPharm series returns to chronicle how treatment of stage III NSCLC has changed over time with an overview of three studies. 1. Dillman (1990) NEJM (sequential chemo --> RT): https://doi.org/10.1056/nejm199010043231403 2. Albain (1995) JCO (concurrent cisplatin/etoposide + RT): https://pubmed.ncbi.nlm.nih.gov/?term=7636530 3. Albain (2009) Lancet (concurrent cis/etposide + RT --> surgery --> consolidation chemo): https://doi.org/10.1016/s0140-6736(09)60737-6

ESMO 2023 Oct 26, 2023

Lots of practice changing new information came out of last week's ESMO conference. This Pod is packed with updates on NSCLC, bladder cancer, gastric cancer, medullary thyroid cancer, KRAS G12C colorectal cancer.....and even bendamustine (non-ESMO update).

Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates Oct 19, 2023

This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial. Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting? West commentary: https://dailynews.ascopubs.org/do/should-induction-chemoimmunotherapy-lead-us-broaden-our-definition-resectability-nsclc

BRAF V600E Updates Oct 12, 2023

Encorafenib + binimetinib gets FDA-approval for metastatic NSCLC, but how does it compare to dabrafenib/trametinib? Plus, a new pediatric approval for dabrafenib/trametinib means more dosage form options.

Press Release Updates Oct 05, 2023

Trying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.

Imatinib [Re-release] Sep 28, 2023

From the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).

Carboplatin Paclitaxel in Ovarian Cancer Sep 21, 2023

It's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago. carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542

HER3-DXd & Motixafortide Sep 14, 2023

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).

RECISTance Is Futile Sep 07, 2023

You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.

DPYD Variant Dosing & ICIs In Pancreatic Cancer Aug 31, 2023

Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651 Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102

Nab-Paclitaxel Aug 24, 2023

A Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.

Niraparib + Abiraterone, Elranatamab, & Melphalan Updates Aug 17, 2023

A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.

Talquetamab & STOP-CA Aug 10, 2023

Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity. STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988

Ruby Trial & Quizartinib Toxicity Aug 03, 2023

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.

BCOP Study Tips Jul 27, 2023

By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.

Chemotherapy Sequencing In Colorectal Cancer Jul 20, 2023

A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI. Some interesting dosing to discuss in this study. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692

Phase 1 Clinical Trials In Oncology with Dr. Donald Harvey Jul 13, 2023

We welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.

Investigational Drug Services In Oncology with Dr. Jackie Saunders Jul 06, 2023

We welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.

NADIM II & Favorable Risk RCC Jun 29, 2023

This episode... More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II. Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.) NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530 FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030

Glofitamab & TALAPRO - 2 Jun 22, 2023

This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3

ASCO '23 Entrees Jun 15, 2023

We highlight notable data from this month's ASCO annual meeting. 1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC 2. ADAURA OS results and low rate of osimertinib use in control arm 3. Keynote 671: perioperative pembrolizumab in NSCLC 4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer? 5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+) 6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease) 7. CARTITUDE-4: Cilta-Cel earlier in MM treatment

ASCO '23 Appetizers Jun 08, 2023

ASCO '23 Appetizers by John Bossaer

PROpel and Cilostazol to Prevent Paclitaxel Neuropathy Jun 01, 2023

Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population. Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol? PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043 Cilostazol RCT: https://doi.org/10.1002/phar.2830 Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514

Epcoritamab May 25, 2023

We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.

Trimodality Treatment For Bladder Cancer May 18, 2023

A recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use. Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5

GAIA-CLL13 & COSMIC-313 May 11, 2023

Today's Pod discusses... 1) A large trial comparing 4 different CLL treatments GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093 2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851 3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809

SUNLIGHT May 04, 2023

Talking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression." SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963

QuANTUM First (Quizartinib 1st Line in AML) Apr 27, 2023

Quizartinib vs. Placebo(?) + Chemo in newly diagnosed AML. We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future. Link: https://doi.org/10.1016/S0140-6736(23)00464-6

ICI + Bacterial Supplementation Apr 20, 2023

We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group. We discuss what to look for in the future studies that are likely to follow with similar methods.

Neoadjuvant Chemo In Breast Cancer Apr 13, 2023

The Landmarks of OncoPharm series returns to discuss NSABP's B18 story of neoadjuvant vs. adjuvant AC in stages I & II breast cancer from 1998. B18: https://pubmed.ncbi.nlm.nih.gov/?term=36989610 Flashback Flashforeward: https://pubmed.ncbi.nlm.nih.gov/?term=36989608

Olanzapine & Pembrolizumab (endometrial, urothelial) Updates Apr 06, 2023

Lots of updates: Olanzapine increases weight gain, QOL in some advanced cancer: https://pubmed.ncbi.nlm.nih.gov/?term=36977285 Chemotherapy Toxicity - When Less is More: https://www.nejm.org/doi/full/10.1056/NEJMcibr1202395 Pembro + Chemo improves PFS > chemo alone in advanced endometrial cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312 Enfortumab vedotin + pembrolizumab gets an accelerated approval for cisplatin-ineligible patients with urothelial carcinoma. Safety signals seen.

[Re-release] Tales of Brave Iressa (2017) Mar 30, 2023

With new Pod this week, we're re-releasing the 2nd episode from way back in 2017 that provides a historical overview of how the use of EGFR TKIs changed from their use in all NSLCLC to only with activating mutations.

Linezolid vs. Vanc In Neutropenic Fever Mar 23, 2023

Not that you always need extended gram positive coverage, but if you did... As is often the case with this Pod, this is mostly providing historical context. Link: https://doi.org/10.1086/500139

Chemo-Induced Ovarian Dysfunction Mar 16, 2023

Prompted by a recent JCO review article (link below), it seemed like a good idea to discuss risks of ovarian dysfunction in women of childbearing potential, what drugs have the highest risk, and fertility preservation techniques. Review article: https://pubmed.ncbi.nlm.nih.gov/?term=29620997 Cyclophosphamide dose equivalent calculator: https://www.oncofertilityrisk.com/CED.html

S1801 (Neoadjuvant Pembro In Melanoma) Mar 09, 2023

We review a clever study looking at neoadjvuant & adjuvant pembrolizumab vs. only adjuvant pembrolizumab in melanoma. Link: 10.1056/NEJMoa2211437 We also discuss some updates on abemaciclib and osimertinib

DA-EPOCH (R) Mar 02, 2023

Landkarmks of OncoPharm: Dose-Adjusted EPOCH (+ R) This episode focuses on the pharmacodynamic rationale for the protocol and delivery, not so much the details of the literature supporting its use. Wilson et al 2002, Blood: https://doi.org/10.1182/blood.V99.8.2685

Cannabis Use With ICIs Feb 24, 2023

Cannabinoids appear to impact immune system function, so could cannabis use blunt the effect of immune checkpoint inhibitors? I don't know, brah. Maybe? Review: https://pubmed.ncbi.nlm.nih.gov/?term=35749680 Cannabis associated with poorer ORR: https://doi.org/10.1634/theoncologist.2018-0383 Cannabis associated with poorer TTP & OS: https://doi.org/10.3390/cancers12092447

Instant KarMMa Feb 16, 2023

Ide-Cel vs. "standard" treatment in relapsed/refreactory multiple myeloma study - the KarMMa-3 trial - is discussed. Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2213614

CodeBreak200 And Elderly AML Survival Feb 09, 2023

CodeBreak200: docetaxel vs. sotorasib in 2nd-line metastatic NSCLC (KRAS-G12C). A new safety signal emerges. https://doi.org/10.1016/S0140-6736(23)00221-0 A new survival prediction model for elderly patients with AML not receiving intensive therapy. https://doi.org/10.1002/cncr.34609

Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib Feb 02, 2023

First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.

HER2 Targeting Era Of Colorectal Cancer Begins Jan 26, 2023

Tucatinib's FDA-approval (with trastuzumab) for HER2 amplified metastatic colorectal cancer launches a new era of targeted therapy in colorectal cancer. Targeting HER2 (amplified in ~3-5% of advanced colorectal cancers) in colorectal cancer will likely evolve over the coming years, so a brief history on how it has evolved so far may be helpful.

Adjuvant Interferon In Melanoma Jan 19, 2023

The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma. ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675 Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354

Breast Cancer In A Nutshell Jan 12, 2023

Broad, big picture overview of breast cancer and its treatment. Ambitious. Do not recommend listening at 1.5x

Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC Jan 05, 2023

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma. And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116

2022 New Drug Review Dec 29, 2022

This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.

Project Renewal: Capecitabine Dec 22, 2022

The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?

ASH 2022 Highlights Dec 16, 2022

Thought on: Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667) Blinatumumab FTW The end of "the" neutropenic diet?

TILs, Olutasidenib, T-DXd Dec 08, 2022

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication Dec 01, 2022

Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.

Mirvetuximab Soravtansine Nov 17, 2022

A new antibody-drug conjugate is approved for ovarian cancer.

Metastatic NSCLC Updates: Role of CTLA-4 inhibitors? Nov 10, 2022

We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC. CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558 POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426 Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

No Room for MABs at the INN Nov 03, 2022

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts. INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#

Tremelimumab & Teclistamab Oct 27, 2022

New Drug Approvals! -Tremelimumab, the 2nd CTLA-4 inhibitor, finally gets approved. -Teclistamab, an excited BCMA-CD3 T-cell engager for multiple myeloma.

Pemetrexed Maintenance Oct 20, 2022

Landmarks of OncoPharm episode on maintenance pemetrexed in NSCLC. Switch maintenance: https://doi.org/10.1016/s0140-6736(09)61497-5 Continuation maintenance (PARAMOUNT): https://doi.org/10.1016/S1470-2045(12)70063-3

Allo CAR-T & Aprepitant For EGFR TKI Pruritis Oct 13, 2022

We discuss a phase I study (CALM) of an allogeneic anti-CD19 CART-T product, using aprepitant (?) for pruritis from EGFR TKIs, and the widely discussed NordICC study on colonoscopy screening. CALM: https://doi.org/10.1016/S2352-3026(22)00245-9 Aprepitant vs. desloratidine: https://doi.org/10.1002/cncr.34474 NordICC: https://www.nejm.org/doi/full/10.1056/NEJMoa2208375 NordICC editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2211595

Futibatinib, ESR1, & GPRC5D Oct 06, 2022

A new FGFR inhibitor, futibatinib, is approved. Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight. What the heck is GPRC5D (rhymes with CAR-T)? PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1 GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900

Thiosulfate And Selpercatinib Sep 29, 2022

Sodium thiosulfate is now FDA-approved to minimize the risk of ototoxicity in some children receiving cisplatin. Selpercatinib is granted a 'regular' approval for RET-fusion (+) NSCLC and an accelerated approval for other solid tumors.

9 22 Sep 22, 2022

Happy 9,22 day!

ESMO 2022 - NICHE-2 and Codebreak 200 Sep 15, 2022

ESMO 2022 is wrapped and two studies in particular have caught our eyes: NICHE-2: neoadjuvant Nivo/Ipi in MMR-d colon cancer CODEBREAK: sotorasib vs. docetaxel

Biliary Tract Cancer & Pemigatinib (unrelated) Updates Sep 09, 2022

Updates on billiary track cancer - a role for durvalumab? And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms. Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)

Temozolomide + RT For GBM Sep 01, 2022

The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM) Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330 Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331

All About Asparaginase Aug 25, 2022

Dr. Amir Ali joins the Pod to cover the Foundations of OncoPharm on asparaginase products

HER2 Mutated NSCLC Aug 18, 2022

In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.

Updated Adjuvant Atezolizumab Data (& more) Aug 11, 2022

New OS data is out for adjuvant atezolizumab in NSCLC - how does it compare to the original DFS data? Plus, lots of recent FDA expanded approvals to discuss.

The Infamous Erlotinib Study Aug 04, 2022

An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul. Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525

Long Term Follow-Up Jul 28, 2022

Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data. ECHELON-1 - Hodgkin's (A+AVD vs. ABVD) POLO - Pancreatic (olaparib maintenance vs. placebo) Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo) APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab) E1912 - CLL (ibrutinib/rituximab vs. FCR)

Living With Lupus Jul 14, 2022

Discussion with a Lupus Nephritis patient (and Pharm.D. student) about manifestations and treatments of SLE and Lupus Nephritis.

ICIs & PPIs - Something to Worry About? Jul 07, 2022

Sifting through and summarizing lots of data on concomitant use of ICIs and PPIs. Suggested readings: 1. All the drugs: https://pubmed.ncbi.nlm.nih.gov/33154150/ 2. Pooled atezolizumab study: https://pubmed.ncbi.nlm.nih.gov/35183773/ 3. Clostridium butyricum may be a thing: https://pubmed.ncbi.nlm.nih.gov/35655708/ 4. AKI risk: https://doi.org/10.21873/invivo.12570 5. Is this all noise?: https://pubmed.ncbi.nlm.nih.gov/35280736/ 6. Abx & PPIs: https://doi.org/10.3389/fimmu.2021.716317

APAP + ICI: An emerging concern? Jun 30, 2022

Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010 Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347

FN Updates Jun 23, 2022

Febrile neutropenia updates on... Short duration antibiotics: https://doi.org/10.1016/S2352-3026(22)00145-4 Same-day pegfilgrastim: https://doi.org/10.2217/fon-2022-0365

LGBTQ Clinical Pearls Jun 16, 2022

Maya Leiva, PharmD, BCOP joins the Pod once again this Pride month to give us some LGBTQ clinical pearls on carboplatin dosing in trans patients and pregnancy/teratogenicity chemo counseling. LGBT Cancer Network: https://cancer-network.org

ASCO 2022 Highlights Jun 09, 2022

Highlights from ASCO's 2022 annual meeting.

Transgender Cancer Screening Jun 02, 2022

Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.

What's Next In NSCLC & AML? May 26, 2022

Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML. NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508 Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4

How To Use Our Favorite Guidelines May 19, 2022

By listener request, we discuss how to utilize our favorite guidelines.

Docetaxel May 12, 2022

A Foundation of OncoPharm: Docetaxel

Adjuvant HD Cisplatin-RT For High Risk Head & Neck Cancer May 05, 2022

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

Melanoma In A Nutshell Apr 28, 2022

The highlights, and only the highlights, of melanoma.

Loong TFRs In CML, A Lack Of Agility, & CHEKCMATE 816 Apr 21, 2022

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).

Ribociclib-Tamoxifen: A Cautionary Tale Apr 14, 2022

Ribociclib-Tamoxifen: A Cautionary Tale by John Bossaer

Relatlimab + Nivo And the VISION trial Apr 07, 2022

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.

HOPA Boston Preview Mar 28, 2022

Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston. Also, great educational programming awaits!

DESTINY-Breast03 Mar 24, 2022

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

Chemo Toxicity Prediction & Risk Mar 17, 2022

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC) Mar 10, 2022

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

7 + 3 Mar 03, 2022

The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3" 7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203

Prostate Ca Updates From ASCO GU 22 Feb 24, 2022

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

Bacillus Calmette-Guerin Feb 17, 2022

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

KIR, HLA - C, & Rituximab Feb 10, 2022

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0 Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187

GI Cancer Updates & Tebentafusp Feb 03, 2022

We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?

Precision Medicine Demystified Jan 27, 2022

Dr. Howard McLeod joins the pod to talk Precision Medicine and the role pharmacists can play using pharmacogenomics and tumor genomics in cancer care. https://www.drhowardmcleod.com

New Hallmarks Of Cancers & LenPembro For Endometrial Cancer Jan 20, 2022

Topic covered include the latest updates to the seminal Hallmarks of Cancer work, adjuvant pembrolizumab for stage IIB/IIC melanoma, a prospective study of UGT1A1 testing, and Keynote-775. Hallmarks of Cancer: New Dimensions. https://cancerdiscovery.aacrjournals.org/content/12/1/31 UGT1A1 Genotype-guided dosing of irinotecan: https://doi.org/10.1016/j.ejca.2021.12.009 Keynote-775: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330

Carfilzomib Jan 13, 2022

Foundations of OncoPharm: Carfilzomib (and a fair bit of bortezomib)

So, You Want to Work (from home) as a Specialty Pharmacist Jan 06, 2022

We're joined by Dr. Ryan McDade to hear about working as a Clinical Pharmacy Lead for Humana Specialty Pharmacy.

Drugs of 2021: Keep, Return Or Re-gift? Dec 23, 2021

Happy Holidays!

ASH21 The More Things Change... Dec 16, 2021

Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.

So, You Want to be a Pediatric Oncology Pharmacist Dec 09, 2021

The 2nd episode in our Career Paths series features Dr. Morgan Randolph. She gives great insight into her role as pediatric oncology pharmacist and the choice between a PGY2 in Pediatrics or Oncology for those considering that decision.

Dasatinib Dosing & DREAMseq Dec 02, 2021

Lots of updates to discuss from dasatinib dosing to ICI/TKI sequencing in BRAF-mutated metastatic melanoma to adjuvant chemo in node (+) breast cancer to some FDA approval updates.

Sun's Out, T Cells Out Nov 18, 2021

Discussing one of the more intriguing studies of the year looking at whether metastatic melanoma survival is effected by what time of day immunotherapy is administered. Link: https://doi.org/10.1016/S1470-2045(21)00546-5

So, You Want To Be An MSL Oncology Pharmacist Nov 11, 2021

What is a medical science liaison (MSL) and what do they do? Our 1st episode in a series highlighting different career options for oncology pharmacists featuring Dr. Christan Thomas.

Asciminib Nov 04, 2021

Asciminib is now FDA approved and it's not just another TKI for CML

Adjuvant Atezo, Palbo-PPI Interaction? And More Oct 28, 2021

From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode. Adjuvant atezolizumab for select NSCLC patients now FDA approved. 5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3 CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1 Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231

Decreased Cardiotoxicity With Infusional Doxorubicin Oct 21, 2021

We return to our Landmarks of OncoPharm series to dive deep into an article that provided some of our foundational understanding of how anthracycline cardiotoxicity risk is influenced by rate of administration. Link: https://pubmed.ncbi.nlm.nih.gov/2910423/

Adjuvant Abemaciclib Oct 14, 2021

FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel. NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.

Same Day Pegfilgrastim Oct 07, 2021

Dr. Ali McBride joins the Pod to spar over same-day vs. next-day pegfilgrastim. (There is some audio feedback early in the Pod that we clean up after a few minutes. Apologies!) Bibliography: Burris et al: https://pubmed.ncbi.nlm.nih.gov/20808556/ AOC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819939/ McBride et al (CHOP): https://www.futuremedicine.com/doi/10.2217/fon-2021-0532 McBride et al (NHL): https://doi.org/10.18553/jmcp.2021.21010

Sarcomas In A Nutshell Sep 30, 2021

An oversimplified approach to thinking about sarcomas.

ESMO21 & New Drugs (Cervical Ca Focus) Sep 23, 2021

Lots to discuss from ESMO 2021 to new drug approvals. First, we discuss the updates in cervical cancer from ESMO (pembrolizumab with chemo) and the newly approved tisotumab-vedotin. Then, we discuss another new agent, mobocertinib and its scary QT prolongation profile as well as cabo-confusion in thyroid cancer. Finally, we discuss the potentially practice changing, but preliminary, data from ESMO in bladder cancer (VESPER) and HER2+ MBC (DESTINY-Breast03).

CASSIOPEIA Part 2 Sep 16, 2021

Discussing the updated results after the 2nd randomization of CASSIOPEIA looking at daratumumab maintenance following ASCT. Link: https://doi.org/10.1016/S1470-2045(21)00490-3

MMF For ITP Sep 09, 2021

Discussing the use of mycophenolate mofetil (MMF) for ITP (https://www.nejm.org/doi/full/10.1056/NEJMoa2100596) as well as regulatory updates on atezolizumab and zanubrutinib.

Hypercalcemia Of Malignancy (in Under 10) Sep 02, 2021

Foundations of OncoPharm: Hypercalcemia of Malignancy (in under 10 minutes)

Belzutifan and Recent Updates Aug 26, 2021

Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved. Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib. Finally, my Top 5 Rolling Stones Songs (14:30).

Booster COVID-19 Vaccinations in Immunocompromised Patients Aug 19, 2021

Looking into the data behind the FDA & CDC's allowance for a booster mRNA vaccine for immunocompromised patients.

Sneaky TKI Toxicities Aug 12, 2021

A recent patient experience serves as a reminder than TKIs, like cabozantinib, can produce many "minor" toxicities that can really add up and affect QOL.

Acala V. Ibrutinib(again) & VidazaAllo Aug 05, 2021

Two recent publications to discuss: 1. The publication of a study discussed on our ASCO '21 Pod on acalabrutinib vs. ibrutinib and patient implications (https://ascopubs.org/doi/pdf/10.1200/JCO.21.01210) 2. A good illustration of the "crossing of the curves" and interpreting Kaplan-Meier curves using alloHSCT vs. 5-aza in MDS patients. https://ascopubs.org/doi/pdf/10.1200/JCO.20.02724

Breast Cancer & cGVHD Updates Jul 29, 2021

Two breast cancer updates (pembrolizumab in TNBC and adjuvant AI duration) and two cGVHD updates (belumosudil and ruxolitinib).

GOG-172 (IP chemotherapy in ovarian cancer) Jul 22, 2021

The almost-award winning* Landmarks in OncoPharm series returns to discuss the landmark Armstrong et al 2006 NEJM paper on using intraperitoneal chemotherapy in stage III ovarian cancer. Link: https://www.nejm.org/doi/full/10.1056/nejmoa052985 *not really

Advertising Amateur Hour Jul 15, 2021

A case study in misbranding promotional materials and how to help FDA regulate them.

Capecitabine Jul 08, 2021

Foundations of OncoPharm: capecitabine

Hormonal Toxicity Management In Breast Cancer Pts Jul 01, 2021

A foundational topic in oncology - managing toxicities of tamoxifen and AI's in breast cancer patients. An excellent evidence-based review was recently published, and is worth our time on the Pod. Link: https://doi.org/10.1016/S1470-2045(20)30666-5

EA1131 & TOURMALINE Jun 24, 2021

So-called negative trials still offer information. We discuss ECOG-ACRIN EA1131 in breast cancer and TOURMALINE-MM1 in myeloma in this epidose. EA1131: https://ascopubs.org/doi/pdf/10.1200/JCO.21.00976 TOURMALINE-MM1 (final OS analysis): https://ascopubs.org/doi/pdf/10.1200/JCO.21.00972

Why Learning Oncology Is Hard Jun 18, 2021

Why is learning oncology so hard? To get the students perspective I ask a few pharmacy students why in hopes of learning how to better teach and precept oncology trainees.

ASCO 2021 Jun 10, 2021

Highlighting results presented at ASCO's 2021 annual meeting.

Sotorasib, Infigratinib, And More Jun 03, 2021

Two new drugs approved in the last week: 1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC 2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.

Amivantamab May 27, 2021

Discussing a first of its kind drug, amivantamab, a bispecific (MET & EGFR) monoclonal antibody just approved for advanced exon20 insertion NSCLC (2nd line).

Venetoclax (with Dr. Kayleigh Marx) May 20, 2021

The Foundations of Oncopharm series tackles veneotoclax with special guest, Dr. Kayleigh Marx - clinical pharmacy specialist in leukemia. She tells us everything we need to know and consider when using venetoclax for leukemia patients. Drug-drug interaction references: 1. https://doi.org/10.1002/jcph.858 2. https://doi.org/10.1016/j.clinthera.2017.01.003 3. https://doi.org/10.1002/jcph.730 4. https://doi.org/10.1007/s12325-018-0793-y

Dosing In Obesity May 13, 2021

ASCO releases updated guidelines for the dosing of cancer drugs in patients with obesity. Not a ton new from the original guidelines, but worthy of discussion. Link: https://ascopubs.org/doi/full/10.1200/JCO.21.00471

Dostarlimab, Loncastuximab tesirine, & HER2 GI Updates May 06, 2021

Two brand new drugs to discuss and their possible roles in practice. Plus, updates on the treatment of HER2-amplified gastric cancer and colorectal cancer.

A Landmark Trial (without an FDA approval) Apr 29, 2021

An abbreviated edition of our Landmarks in #OncoPharm series returns to discuss weekly cisplatin + radiotherapy for locally advanced cervical cancer. As a bonus, we cover a new study establishing FOLFOX as the standard-of-care for 2nd line treatment of metastatic biliary cancer. All of this is discussed against the backdrop of the relative importance (or lack thereof?) of obtaining an approved indication.

COVID Vaccine (Myeloma & CLL), MANHATTAN And More Apr 22, 2021

First, we review some early evidence of antibody response following COVID vaccination in patients with multiple myeloma and CLL. Then, we discuss nivolumab's approval with chemo for first-line treatment of gastric cancer (& GEJ & adenocarcinoma of the esophagus) and the MANHATTAN study and its high rate of MRD-negativity in myeloma. 5-yr OS data is published for pembrolizumab in PD-L1 > 50% NSCLC and a new drug is approved for the 1st time while recording the Pod.

IO Uh Oh Apr 15, 2021

Immunotherapy (IO) takes a few steps back as several prior accelerated approvals are withdrawn...with possibly more bad news to come.

Cancer COVID Vaccine Updates + AMBORO Apr 08, 2021

Updates on COVID-19 vaccination in cancer patients on immune-checkpoint inhibitors (new data!) and those getting imaging studies after vaccination. We quickly run through the AMBORO (April 6 published online in J Clin Oncol) trial demonstrating improvements in patient care with the inclusion of a clinical pharmacist (or pharmacologist) in managing PO antineoplastics.

ICIs In Esophageal & GEJ Cancers Apr 01, 2021

Updates on the use of immune-checkpoint inhibitors in esophageal and gastro-esophageal junction (GEJ) cancers. First, adjuvant nivolumab (Checkmate 577). Then, pembrolizumab + chemo for initial treatment of metastatic disease (Keynote 590). Also, we mention 2 new approvals for myeloma: the 1st CAR-T for the disease and an expanded indication for isatuximab.

Emend's Emergence Mar 25, 2021

The Landmarks of OncoPharm series returns to discuss 2 pivotal trials that ushered in the age of aprepitant and NK-1 receptor anagonists for CINV. Aprepitant in HEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2003.01.095 Aprepitant in MEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.09.050

Tivozanib (and More) Mar 18, 2021

Tivozanib's FDA approval for mRCC was a long time in the making, but what is its role? Disappointing atezolizumab results for adjuvant treatment of bladder cancer (IMvigor-010). Preliminary data on antibody responses to COVID-19 vaccination in cancer patients.

Indolent Lymphoma Week Mar 12, 2021

This week, two indolent lymphoma updates: 1. CAR-T (Axl-Cel) for follicular lymphoma 2. Is there a preferred platinum salt in DHAP for Mantle cell lymphoma* patients heading to transplant? (https://pubmed.ncbi.nlm.nih.gov/33658645/) *Yes, I know - not really an indolent lymphoma in this case.

Melphalan Flufenamide Mar 04, 2021

Melphalan flufenamide, a drug that makes tumor cell kinetics cool again, is our main topic. Also, brief updates on lorlatinib (ALK+ mNSCLC) and nivolumab/cabozantinib (mRCC).

Trilaciclib, Cemiplimab & GU Updates Feb 25, 2021

Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC

Filgrastim Turns 30 Feb 18, 2021

Happy Birthday to a drug that ushered in its own era! We discuss its history and development and just a little bit about its benefit, role, and a few clinical pearls.

Umbralisib Feb 11, 2021

Discussing the latest TKI approval, umbralisib, and its familiar toxicity profile. Also, a few final words on a new CAR-T product and a cemiplimab expanded approval.

Tepotinib Feb 04, 2021

In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.

Updates on mRCC and COVID-19 Vaccination Jan 28, 2021

With the recent FDA-approval of nivolumab + cabozantinib for metastatic renal cell carcinoma (mRCC, we review Checkmate-9ER results and how they compare to other combination treatments in mRCC. We then end by discussion preliminary recommendations on vaccinating patients with cancer agains COVID-19. Checkmate-9ER abstract: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkmate-9er-trial

Updates T-DXd (gastric) & SC Dara (AL Amyloidosis) Jan 21, 2021

Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis. DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413

JBR10 Jan 14, 2021

Our landmarks of OncoPharm series returns to discuss JBR10, adjuvant cisplatin/vinorelbine in NSCLC. JBR10: https://www.nejm.org/doi/pdf/10.1056/NEJMoa043623 JBR10 Update: https://pubmed.ncbi.nlm.nih.gov/19933915/ LACE meta-analysis: https://pubmed.ncbi.nlm.nih.gov/18506026/

Updates from December 2020 Jan 07, 2021

The 1st episode of 2021 covers 5 FDA updates from December 2020 -Pralsetinib for RET-mutated medullary thyroid cancer -The new HER2-targeting margetuximab -Selinexor and the Boston study -Relugolix, an oral GnRH antagonist -Adjuvant osimertinib approved (ADAURA)

Trastuzumab Dec 31, 2020

Our Foundations of Oncopharm series returns to discuss the history and use of trastuzumab.

Best Of 2020 Dec 23, 2020

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.

COVID Vaccines In Cancer Patients - What We Don't Know Dec 17, 2020

COVID-19 Vaccines are here!!! Will they work in patients on chemo? What about immunotherapy? Without firm answers to such questions we might as well talk about mRNA vaccines, the breakout star of 2020.

Breast Cancer Updates Dec. 2020 Dec 11, 2020

First up we discuss RxPonder and what it adds to adjuvant treatment of breast cancer in the context of TailoRx. Then we discuss a recent study (https://jamanetwork.com/journals/jama/fullarticle/2774295)of additional capecitabine following adjuvant chemo in TNBC and what it adds in the context of CREATE-X.

Colon Cancer Updates (IDEA & Keynote - 177) Dec 03, 2020

Final OS results are now available for IDEA - 3 vs. 6 months of adjuvant chemotherapy for colon cancer: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30527-1/fulltext Keynote-177 (pembrolizumab for MSI-H/dMMR metastatic colorectal cancer) was presented at ASCO, but interim results are now published as well: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

CLOT Nov 24, 2020

The Landmarks in OncoPharm series returns to discuss the practice-changing CLOT trial of a LMWH vs. a vitamin K antatogist for treating cancer-associated VTE. CLOT: https://www.nejm.org/doi/full/10.1056/nejmoa025313

Pembrolizumab for TNBC & CML Updates Nov 19, 2020

Pembro gets an approval for triple negative breast cancer with quite high PD-L1 expression based on Keynote-355 (https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1000). Some reassuring information on TKI discontinuation in CML from the LAST study (doi:10.1001/jamaoncol.2020.5774) and an interesting method of identifying predictors of TKI adherence in CML (https://journals.sagepub.com/doi/pdf/10.1177/1078155220970616).

Ifosfamide Nov 12, 2020

Our Landmarks of OncoPharm series returns with Ifosfamide

BELLINI Nov 05, 2020

The BELLINI trial of venetoxlax in multiple myeloma was put on hold last year due to increased mortality. It's now published (https://doi.org/10.1016/S1470-2045(20)30525-8), so we take a look at the data and the myriad of supportive care concerns.

Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT Maintenance Oct 29, 2020

Discussing three recent publications: 1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8) 2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272) 3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)

Monthly Immunotherapy Expanded Approvals Update Oct 21, 2020

Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.

Fulvestrant's Fumbled Dosing Oct 15, 2020

Fulvestrant's standard dosing is now 500 mg IM on Days 1, 14, 29 & then monthly thereafter. Its initial FDA-approved doing was half that with no loading dose, 250 mg IM monthly. So, how did we come to underdose an antineoplastic for almost a decade?

Dexamethasone Oct 08, 2020

Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.

IMpower 110 & Checkmate 153 Oct 01, 2020

Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about. IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346 Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131

ESMO 2020 & Beyond Sep 24, 2020

Updates from ESMO 2020 & more on: Bladder Cancer (JAVELIN Bladder 100 & DANUBE) Lung Cancer (ADAURA & CROWN) Breast Cancer (ASCENT, IMPASSION 130/131, monarchE) And the first major publication of drugging the "undrugable" KRAS

TAX 327 Sep 17, 2020

The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory. TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720

Pralsetinib Sep 11, 2020

We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.

BROCADE3 Sep 03, 2020

After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment. BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-2

Alopecia Aug 27, 2020

Chemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.

ATAC Aug 20, 2020

Our Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.

VIALE-A (venetoclax + azacitidine for elderly/unfit AML) Aug 13, 2020

VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity. Link: https://doi.org/10.1056/nejmoa2012971

New Anti-CD-19 And BCMA Options Aug 06, 2020

Lots of new options for B-cell malignancies of all ages! We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate). Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.

Gemcitabine Jul 30, 2020

Next up in the Foundations of #OncoPharm series, gemcitabine.

Antiemetic & CIPN Guideline Updates Jul 23, 2020

We summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN). Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?

Conversation With A Breast Cancer Survivor Jul 16, 2020

We're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.

Neutropenic Fever 101 Jul 09, 2020

While this is a topic best covered with case examples, we do our best to provide the basics in 20 minutes. Experienced clinicians may not be aware of the How Long study briefly discussed in this episode: https://doi.org/10.1016/S2352-3026(17)30211-9

Early July FDA Updates Jul 02, 2020

FDA ended June with 5 new approvals. *selinexor for r/r DLBCL *pembrolizumab for cutaneous squamous cell carcinoma *pembrolizumab for MSI-h/dMMR met. colorectal cancer *avelumab maintenance for met. bladder cancer *SC trastuzumab/pertuzumab/hyaluronidase

Clinical Trial Endpoints in Oncology Jun 25, 2020

A primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.

Lurbinectedin et al Jun 18, 2020

Topics on this week's Pod include: -Lurbinectedin in SCLC -Nivolumab is esophageal cancer -Pembrolizumab for TMB-high cancers -Gemtuzumab ozogamicin for pediatric AML -Venetoclax + HMA for adult (unfit) AML -Gardasil for prevention of SCCHN -Perhaps the biggest non-oncopharm news of the year?

LD Vs Ld Jun 11, 2020

LD Vs Ld by John Bossaer

ASCO 2020 Jun 04, 2020

Recapping lots of updates from ASCO 2020. Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.

More NSCLC Updates (Checkmate-9La & ALTA-1L) May 28, 2020

Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC). Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors. (Lots of ASCO talk *next* week!)

New Chemo - Free Immunotherapy Options For NSCLC May 21, 2020

There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.

Selpercatinib & More! May 14, 2020

We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target. Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30). Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cholangiocarcninoma. RET fusions: https://doi.org/10.1016/j.ctrv.2019.101911 PAOLA-1: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361 IMbrave150: https://www.nejm.org/doi/full/10.1056/NEJMoa1915745 Olanzapine: https://jamanetwork.com/journals/jamaoncology/article-abstract/2765323 Ivosidenib in cholangiocarcinoma: https://doi.org/10.1016/S1470-2045(20)30157-1

Capmatinib & SC Daratumumab May 08, 2020

First, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase. We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.

Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin Apr 30, 2020

Topics of discussion: Q 6 week pembrolizumab dosing schedule FDA approved Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28) The monarcHER study of abemaciclib in HER+ MBC (12:20) The GRIFFIN study of Dara+VRD in myeloma (17:00)

Sacituzumab Govitecan, Tucatinib, And More! Apr 24, 2020

Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.

Journal Club: Unscheduled Hydration in Patients Receiving HEC Apr 16, 2020

Our 1st Journal Club. 1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787 2. Ask how, or if, this would change practice. 3. Listen.

Bevacizumab's Wild Ride For Metastatic Breast Cancer Apr 09, 2020

First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer. Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1). Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs... E2100: https://www.nejm.org/doi/full/10.1056/nejmoa072113 Avado: https://www.ncbi.nlm.nih.gov/pubmed/20498403 Ribbon-1: https://www.ncbi.nlm.nih.gov/pubmed/21383283

Caravaggio Apr 02, 2020

Reviewing the lasted DOAC study in treating cancer-associated VTE: Caravaggio. We compare it the other major DOAC studies in this patient population. Caravaggio: https://www.nejm.org/doi/full/10.1056/NEJMoa1915103 Also, announcing our first journal club! This will be our 4/16 Pod. It is especially for an oncology APPE students missing out on an oncology experience, but all are welcome to participate. Journal Club link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0787

Bleomycin Mar 27, 2020

The Foundations of OncoPharm series returns with a unique chemotherapy drug: bleomycin. Also, Covid Thoughs (14:00).

Recent Landmarks (CLEOPATRA, Keynote189) Mar 19, 2020

Recent updated survival analyses for CLEOPATRA and Keynote-189 (6:45) require some historical context to truly see their impact. Finally, #AskOncoPharm returns (15:05) with a listener question about infusion rates when restarting daratumumab.

*Covid19 And Chemo* Mar 16, 2020

We all should do what we can to "flatten the curve" and that includes our patients on treatment. While there is no such thing as elective chemo, there are some practical ways we can minimize patients needing to come into our facilities.

Viz-Aflibercept Pricing: A Case Study Mar 12, 2020

Looking back at a 2012 NYT op-ed (https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html) that led to a 50% price decrease in a biologic cancer medication.

Pre - HOPA News Dunp Mar 05, 2020

A plethora of #oncopharm updates! Isatuximab is approved and neratinib gets another breast cancer indication (2:00) Pembrolizumab with chemo for triple-negative breast cancer (8:50) New EPOC updated survival analysis on FOLFOX+cetuximab in isolated liver metastatic colon cancer (15:00) Precision medicine in pancreatic cancer (19:30) Cladribine + rituximab for hairy cell leukemia (23:30)

CYP2D6 & Tamoxifen Updates Feb 27, 2020

Two recent publications add to our knowledge concerning the utility of CYP2D6 genotyping and tamoxifen. TARGET-1: https://www.ncbi.nlm.nih.gov/pubmed/31821071 Tamoxifen D/C rates by 2D6 genotype: https://www.ncbi.nlm.nih.gov/pubmed/31800347

CAR - NK Feb 13, 2020

You've heard of CAR-T therapy, and now it's time to learn about CAR-NK cells. Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa1910607

NK - 1 Antagonist Drug Interactions Feb 06, 2020

Drug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant. A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).

Tazemetostat Jan 30, 2020

All the need-to-know items about the latest #oncopharm approved drug, tazemetostat, to start the Pod. We end (9:15) with a brief discussion of how gut bacteria may lead to gemcitabine resistance.

Bendamustine Jan 23, 2020

Foundations of OncoPharm: Bendamustine

Avapritinib Jan 16, 2020

New Drug Update! We discuss the efficacy and safety data surrounding avapritinib's approval as well as its likely role in GIST management.

Safety Signals & 6 - MP Hepatotoxicity Jan 09, 2020

How common are upon safety concerns from FDA on newly approved #oncopharm agents? Does the accelerated approval process lead to more safety updates? We discuss (https://doi.org/10.1634/theoncologist.2019-0653). We also look at a possible way to mitigate 6-MP hepatoxicity (5:45) using allopurinol (https://doi.org/10.1080/10428194.2019.1702183). Finally (10:55) we review the most recent FDA indications for olaparib and pembrolizumab.

Trastuzumab Deruxtecan Jan 02, 2020

Kicking off the 2020 Pod season with the last FDA-approval of 2019 - trastuzumab deruxtecan.

Enfortumab-vedotin (& Asciminib) Dec 26, 2019

Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!

Arsenic Sauce Dec 19, 2019

The Foundations of #OncoPharm series combines with a thematic critique of an animated Holiday classic to examine the links between The Grinch and Arsenic Trioxide.

ASH '19 Updates Dec 12, 2019

Reviewing pertinent abstracts from ASH's 2019 annual meeting. Abstracts discussed: LBA-1 (blinatumomab), 2640 (venetoclax-azoles interactions), 2639 (FLAG/CLAG vs. CPX-351 in sAML), LBA-6/862/860 (myeloma), and 3310 (PK-targeted dosing of melphalan for autoHSCT). Search here: https://ash.confex.com/ash/2019/webprogram/start.html

Dose Dense AC Dec 05, 2019

The Landmarks in #OncoPharm series returns with dose-dense AC, published in JCO in 2003 by Citron et al. Link: https://www.ncbi.nlm.nih.gov/pubmed/12668651

Cornucopia Of OncoPharm Updates Nov 27, 2019

The menu: sirolimus vs. prednisone for standard risk aGVHD, levofloxacin prophylaxis in myeloma patients (9:00), acalabrutinib's approval for CLL/SLL (12:00), OS analysis from osimertinib's FLAURA (14:30), optimal sequencing of abiraterone & enzalutamide (23:20), some novel non-malignant heme drugs (26:45), outro music (30:00), 2 new drugs for sickle cell (30:30), pecan pie.

Zanubrutinib Nov 21, 2019

BTK-targeting therapy approved again! Zanubrutinib approved for Mantle Cell Lymphoma (2nd line) - how does it compare to ibrutinib and acalabrutinib?

Immunotherapy Interactions Nov 14, 2019

Examining the effects of antibiotics, corticosteroids (6:45), and cannabis (12:05) on immunotherapy effectiveness.

Data Dive Into NK-1 Antagonists & Carboplatin Nov 07, 2019

ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.

Carboplatin Oct 31, 2019

The basic must-know information for carboplatin, for students, residents, or anyone looking for a refresher.

ADAM VTE & Ibrutinib CV Toxicity Oct 24, 2019

ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.

To Rechallenge, Or Not To Rechallenge Oct 17, 2019

Weighing the risks & benefits of immunotherapy rechallenge in patients with a prior immune-related adverse event (irAE). Reference: https://www.ncbi.nlm.nih.gov/pubmed/31461381

CASPIAN Oct 10, 2019

Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.

ESMO 2019 Oct 03, 2019

Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.

Danorubicin 90 mg/m2 (AML induction) Sep 24, 2019

The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.

New FDA approved indications for lenvatinib, pembro, and apalutamide Sep 19, 2019

Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.

Curious Case Of Ibrutinib On Netflix Sep 12, 2019

Recapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.

OncoPharm M & M Extreme Toxicity & Pharmacogenetics Sep 05, 2019

The 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org

Irinotecan Aug 29, 2019

The Foundations of #OncoPharm series returns with all the must-know information for irinotecan.

Entrectinib & Fedratinib Aug 22, 2019

Running through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.

E1912: Ibrutinib/rituximab vs. FCR in CLL Aug 15, 2019

This week we look at the NEJM publication earlier this month (https://www.nejm.org/doi/full/10.1056/NEJMoa1817073) of E1912. Points of discussion include IGHV mutational status, PFS vs. OS as endpoints in CLL, the benefit of rituximab in addition to ibrutinib, and ibrutinib toxicity in younger vs. older CLL patients. (Also, apologies to my APPE student for dropping this Pod *after* your journal club on this paper.)

ASCO VTE Guidelines (& more!) Aug 08, 2019

Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).

Darolutamide Jul 31, 2019

Darolutamide has been FDA-approved. We discuss its differences and similarities to other 2nd-generation anti-androgens (enzalutamide & apalutamide) - especially potential drug interactions!

AC - - > T (q week) Jul 25, 2019

Our Landmarks in #OncoPharm series returns to the breast cancer patient population to review the landmark 2008 NEJM article from Sparano et al (https://www.nejm.org/doi/full/10.1056/NEJMoa0707056) investigating the optimal taxane regimen to follow adjuvant AC.

Selinexor Jul 18, 2019

A brief discussion on FDA's approval decision on selinexor and its possible role in therapy. Then, a more in-depth details on its MOA, dosing, and toxicity profile.

Pain Management In Cancer Jul 11, 2019

An overview of pain management principles in cancer patients. Topics covered include the role of NSAIDs, bisphosphonates, and opioids in treating or preventing pain. Also discussed: bowel regimens & opioid conversions.

Tamoxifen Jul 03, 2019

The Foundations in #Oncopharm series returns with the story of a failed contraceptive candidate that became the first (?) targeted therapy for use in cancer. Tamoxifen's use, MOA, toxicities, and drug interactions are also discussed.

Ask OncoPharm: Advice for PGY2 Oncology Pharmacy Residents Jun 27, 2019

We open up the Ask #OncoPharm inbox to answer a listener question - What advice do you have before starting my PGY2 Oncology Pharmacy Residency?

Pembrolizumab Nets 2 More Approvals Jun 20, 2019

Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)

Polatuzumab-vedotin Jun 13, 2019

A newly approved drug for relapsed/refractory diffuse large B-cell lymphoma is discussed as well as PBR.

ASCO '19 Jun 06, 2019

Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan. *caveats apply

Alpelisib May 30, 2019

Discussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...

AC - - > T (q 3 week) May 23, 2019

The Landmarks in #OncoPharm continues down its breast cancer-centric track with the landmark CALGB 9344 trial that established the role of paclitaxel in the adjuvant setting --> https://ascopubs.org/doi/pdf/10.1200/JCO.2003.02.063

AC (NSABP B-15) May 23, 2019

The Landmarks in #OncoPharm series returns with a discussion of NSABP B-15, which established AC as a standard adjuvant chemo regimen for breast cancer --> (https://ascopubs.org/doi/abs/10.1200/JCO.1990.8.9.1483)

May Approvals, More Questions May 16, 2019

Running through updated FDA approvals from this month (ivosidenib, T-DM1, ramucirumab, avelumab/axitinib, & venetoclax/obinutuzumab) and how these approvals raise more questions.

Imatinib May 09, 2019

The Foundations of OncoPharm returns with imatinib, the 1st TKI. Discussion includes its history (and how imatinib's Phase I study almost didn't happen), uses, and toxicity.

Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML May 02, 2019

Discussion of 2 important malignant hematology updates: the NEJM publication of the 1st published results of CAR-T therapy in multiple myeloma and the FDA-approval of ivosidenib in frail AML patients (with IDH1 mutations).

Lenvatinib vs. Sorafenib (HCC) Apr 24, 2019

Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.

Erdafitinib Apr 18, 2019

Summary of erdafitinib's FDA-approval including dosing, MOA, toxicity, and (wait 'til the end) prevalence of FGFR mutations. Ifos. Eye-Phos.

HOPA '19 Reflections Apr 11, 2019

Reflections offered from HOPA's 2019 annual conference on cabozantinib, regorafenib, low-dose azacitidine, SC granisetron (this is a thing), clinical trial hope, and opportunities for students in HOPA

OncoPharm M & M - Drug Interaction Apr 02, 2019

Debut of a new feature: OncoPharm M & M, where we'll discuss notable case reports of #oncopharm misadventures....how they happened...and how we can prevent them in the future. Our first installment in this series discusses a drug interaction between idelalisib & diazepam (Case Report Link: https://doi.org/10.1177%2F1078155216653705).

Etoposide Mar 28, 2019

Our Foundations in #OncoPharm returns with etoposide, including a deeper than necessary discussion of the historical medical(?) uses of podophyllotoxins, its MOA, uses, and toxicities.

Updates: Venetoclax use in multiple myeloma, atezolizumab in small cell lung cancer Mar 21, 2019

This week brought several notable updates we discuss: the FDA's concern with a venetoclax clinical trial in multiple myeloma patients, atezolizumab's expected FDA-approval for small cell lung cancer, and some neuro-oncology guideline endorsements.

Metastatic Pancreatic CAncer Mar 14, 2019

Brief background on metastatic pancreatic cancer is provided, followed by a brief discussion of the main landmark clinical trials (and one not-so-landmark study) in this difficult disease state.

S.C. Monoclonal Antibodies Mar 08, 2019

Coming to a P & T committee meeting near you....it's subcutaneous (S.C.) monoclonal antibodies. We discuss the two currently FDA-approved formulations: rituximab + hyaluronidase and trastuzumab + hyaluronidase.

Lessons Learned (from the last week) Feb 28, 2019

Providing some clinical pearls learned in the last week regarding patient education for ruxolitinib & alectinib. Then (11:50) we recap follow-up publications from Keynote-24 & the BRIGHT studies, before finishing up the week's journal scan with a discussion of the optimal dose of nivolumab + ipilimumab in melanoma and who may NOT benefit from palbociclib.

Axitinib's Big Weekend Feb 21, 2019

Axitinib studies presented at ASCO-GU '19 with simultaneous NEJM publication are discussed, followed by a brief overview (18:50) of darolutamide, a new anti-androgen, and its drug interaction potential.

IRIS Feb 14, 2019

The Landmarks in Oncology Pharmacy series returns to discuss the International Randomized Study of Interferon vs. STI571 (imatinib) aka IRIS.

Cannabidiol (CBD) & Potential Drug Interactions In Cancer Patients Feb 07, 2019

CBD use is becoming more widespread in society, including in cancer patients. Potential, and significant, drug interaction concerns should be considered.

Mucositis & Stomatitis Jan 31, 2019

Mucositis & stomatitis are basically interchangeable terms for one of the hallmark chemotherapy toxicities. We discuss its pathophysiology, prevalent, and prevention/treatment.

Olaratumab, Goodbye? Jan 24, 2019

Olaratumab received accelerated approval in 2016 under the condition a phase III study would confirm its benefit. It didn't. We explore some possible explanations why a seemingly promising drug for a tough disease hasn't panned out...

Conversation With An Osteosarcoma Survivor Jan 17, 2019

It's always enlightening to talk to a cancer survivor and is an essential part of the patient care process. This conversation touches on chemo-induced toxicities (e.g. ifosfamide neurotoxicity), supportive care advances (olanzapine!), and the anxiety of survivors live with while living scan-to-scan. Brought to you by the Bill Gatton College of Pharmacy.

New & Niche Drugs Jan 10, 2019

We finish discussing the 2018 FDA-approvals (calaspargase, ravulizumab, tazgraxofusp).

mFOLFIRINOX Jan 03, 2019

New year, new chemo regimen to discuss. We go over mFOLFIRINOX for adjuvant pancreatic cancer from the recently published PRODIGE-24 study. We discuss out the regimen is modified, where to find dose reductions, and how many patients required G-CSF.

Let's Talk About Mr. Gower Dec 20, 2018

Keeping it light this Holiday Season with a discussion of the portrayal of pharmacists, notably Mr. Gower from It's a Wonderful Life, in pop culture. Regular Pods return in 2019.

FOLFOX (MOSAIC Trial) Dec 13, 2018

The Landmarks in Oncology Pharmacy series returns with a discussion of MOSAIC: FOLFOX adjuvant chemotherapy for stage ii & STAGE III colon cancer.

Gilteritinib Dec 05, 2018

Another week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F1078155218802620

Elderly AML & Larotrectinib Nov 27, 2018

The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.

Rise (& Fall) Of ESAs Nov 21, 2018

Describing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.

Cyclophosphamide Nov 15, 2018

Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.

Lorlatinib Nov 06, 2018

Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?

October '18 Updates Nov 01, 2018

Running through recent notable updates on pembrolizumab, olaparib, atezolizumab, palbociclib and 5F9's introduction.

Flu Vaccine Use with Immunotherapy Oct 25, 2018

Discussing the scant evidence regarding influenza vaccination in cancer patients receiving immunotherapy. Warning! - unpublished abstracts are discussed by a guy with laryngitis.

Talazoparib Oct 18, 2018

Another new #oncopharm agent was approved. We talk about talazoparib and how it compares to olaparib for germline BRCA-mutated breast cancer.

P1: Tamoxifen for Breast Cancer Risk Reduction Oct 11, 2018

The Landmarks in Oncology Pharmacy series returns with the P1 study. We review this landmark paper paving the way for breast cancer risk reduction (or chemoprevention) and discuss the mark or lack thereof (frown emoji) it has made in clinical practice.

Dacomitinib, cemiplimab & #oncopharm updates Oct 04, 2018

Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.

Duvelisib Sep 26, 2018

The latest #oncopharm approval for duvelisib is discussed as well as the similarities and differences to other PI3K inhibitors previously approved.

The Pseudomonas Exotoxin Drug Sep 20, 2018

Discussing the new pseudomonas exotoxin drug (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia (3rd line). Lots of supportive care measures required, surprisingly, for the pseudomonas exotoxin drug.

*Bonus Pod* World Marrow Donor Day '18 Sep 15, 2018

Celebrating World Marrow Donor Day by recapping the HSCT donation experience of your favorite podcast host.

5-Fluorouracil Sep 14, 2018

5-FU: both its mechanisms, all its toxicities, most of its uses, and some of its history are discussed.

Ask OncoPharm (Part 1) & RELEVANCE Sep 06, 2018

The debut of our mailbag (Ask OncoPharm) to give some tips to new oncology pharmacists. Then (13:10) we review the RELEVANCE study of rituximab/lenalidomide in follicular lymphoma.

Influenza Vaccination during Chemo Aug 30, 2018

It's flu shot season, so we're taking a pseudo-systematic review of influenza vaccination in patient receiving chemotherapy. Questions addressed include: How effective is influenza vaccination for cancer patients? What's the optimal timing of vaccination during chemo?

Small Cell Lung Cancer: Established & Recent Advances Aug 23, 2018

Small cell lung cancer is reviewed, including the milestone advances (chemo + RT, omitting surgery, cis/etoposide) of the past leading up to the latest advance (15:20) - FDA-approval of nivolumab in the 3rd-line setting.

Mogamulizumab & August updates Aug 16, 2018

Mogamulizumab-kpkc (MOAs, administration, toxicity) and its FDA-approval is discussed followed by (9:00) updates lenvatinib (a good update) and azithromycin (a bad update) in cancer patients.

Rituximab Aug 09, 2018

We explore the origins of rituximab's dose, geek out on the NNT in DLBC, and discuss other "need to know" tidbits.

Iobenguane I-131 & Lusutrombopag Aug 02, 2018

Catching up the recent FDA-approvals for iobenguane I-131 (and its myriad of precautions) and lusutrombopag.

Ivosidenib Jul 26, 2018

After running through recent FDA updates (including ribociclib's approval in PRE-menopausal breast cancer patients), the newly approved ivosidenib is discussed.

A Brief History of Pemetrexed Jul 20, 2018

Ten years ago a preplanned subgroup analysis changed the NSCLC treatment algorithms. We go back to the beginning with pemetrexed and the studies leading up to the oft-cited Scagliotti that ushered in histology-specific treatment in NSCLC.

Paclitaxel Jul 11, 2018

We discuss paclitaxel, from its discovery to its uses to toxicity and their management as part of our Landmarks in #OncoPharm series. And if you really, really love this drug - you'll learn where to may homage at a historical marker in....

Happy Fourth! Jul 04, 2018

Our shortest Pod yet! Chemotherapy explosions and photosensitizing antineoplastics are discussed.

Encorafenib & Binimetinib Jun 28, 2018

The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.

The Immunotherapy Two Step Jun 21, 2018

Immunotherapy takes two steps forward (new FDA approvals)....and two steps backwards. These updates in #oncopharm are discussed before ending (11:45) with discussions of venetoclax's expanded approval in CLL, the bevacizumab approval almost 7 years in the making, and late-breaking information on preventing cisplatin ototoxicity.

Ondansetron Origins Jun 13, 2018

The Landmarks in Oncology Pharmacy series returns with a review of 2 ondansetron studies from 1990, published simultaneously in NEJM.

Less is More & More Jun 07, 2018

Recapping (some) of the top stories from ASCO18 starting with breast cancer (TAILOR-Rx, PERSEPHONE, SANDPIPER, S0927); then NSCLC (11:35) with Keynote-42 & LOXO-292; then mylemoa (16:50) with a CAR-T update and a new dosing of carfilzomib; before ending (20:30) with CARMENA and PRODIGY-24's new mFOLFIRINOX data for adjuvant pancreatic cancer. Whew!

ASCO18 & Under the Radar Abstracts May 31, 2018

Previewing this week's ASCO annual meeting and the Plenary Sessions (briefly) and selected abstracts highlighting oncology pharmacy practice.

Avatrombopag May 25, 2018

Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.

PERSEPHONE: Bonus Pod May 19, 2018

The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.

Cytarabine May 18, 2018

Cytarabine, the 'c' chemotherapy from the sea, is discussed.

Dual TKI Use & Frontline Dara May 10, 2018

Recent FDA updates are discussed including combined use of BRAF & MEK inhibitors, frontline daratumumab (10:20), and your next P & T monograph drug to review.

Methotrexate May 04, 2018

The foundations of #oncopharm series continues with methotrexate. We begin with its origin story and end discussion modern-day use in high doses.

AACR Update Apr 19, 2018

Recent FDA & #oncopharm updates are discussed, including irinotecan in sweat, fostamatinib's FDA-approval for ITP. Then, immunotherapy updates from AACR are reviewed (6:00). Finally (34:00 , osimertinib's updated approval for frontline use in mEGFR NSCLC.

NSABP-14 Apr 13, 2018

You've heard of NSABP, but have you heard of adjuvant melphalan, 5-FU, & concurrent tamoxifen? Sometimes asking the right question yields answers we don't yet understand.

Vincristine Apr 06, 2018

The Foundations in Oncology Pharmacy continues with vincristine. Its origin, unique toxicity profile, and clinical use is discussed. Periwinkle!

HOPA Highlights and Catching Up with NEJOncology Mar 30, 2018

Highlights from last week's HOPA annual conference are discussed, followed by (13:09) a lightning-style run through of #oncopharm updates over the last 2 weeks.

HOPA Preview Mar 16, 2018

Previewing HOPA18 and its highly anticipated sessions, networking opportunities, and virtual attendance.

Landmark Testicular Cancer Study PVB (& BEP & EP) Mar 09, 2018

PVB's (cisplatin, vinblastine, bleomycin) impressive cure rate for testicular cancer is 1977 is discussed. Then the evolution of the BEP & EP regimen is summarized.

Cycling thru the CDK Inhibitors Mar 01, 2018

Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.

It's All Immunotherapy Nowadays Feb 23, 2018

Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.

Apalutamide Feb 15, 2018

Apalutamide's FDA-approval is discussed, including discussion of its drug interaction potential and a review of the SPARTAN study. Updates (18:15) from ASCO GU and DOAC use in cancer (23:50) also discussed.

Landmarks in Oncology Pharmacy: CMF Feb 09, 2018

The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.

Foundations in Oncology Pharmacy: Doxorubicin Feb 02, 2018

Overview of doxorubicin from its Italian origins to its Red Devil alias. Uses and toxicities also discussed, of course.

Updates in Oncology Pharmacy: Lu-177 Jan 26, 2018

New Drug Approval: Lutetium-177-dotatate is discussed as well as updates to indications for denosumab (m. myeloma), afatinib, & olaparib.

Landmarks in Oncology Pharmacy: MOPP Jan 19, 2018

The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.

Foundations in Oncology Pharmacy: Cisplatin Jan 12, 2018

The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML) Jan 05, 2018

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Landmarks in Oncology Pharmacy: Acute Leukemia in 1958 Jan 01, 2018

In the 1st of the Landmarks series, we look back at a pivotal article published in Blood in 1958 on the treatment of acute leukemia.

2017 Was A Good Year Dec 18, 2017

2017 saw A LOT of #oncopharm approvals. Oncology pharmacist & educator John Bossaer runs through some of the most notable oncology pharmacy trends of the year, include CAR-T cell therapy

Tales of Brave Iressa Nov 30, 2017

Discussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.

Adjuvant TKIs? Nov 17, 2017

Recent FDA updates & a brief discussion about adjuvant TKI use in solid tumors.

Acalabrutinib Nov 01, 2017

Oncology Pharmacy Podcast discussing the FDA-approval of acalabrutinib